Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact firstname.lastname@example.org.
SOURCE Cyberonics, Inc.
HOUSTON, Feb. 19, 2014 /PRNewswire/ -- Cyberonics, Inc. (NASDAQ:CYBX), a global leader in medical devices for the treatment and management of epilepsy, today announced it will participate in the following conferences.
Greg Browne, Cyberonics' Chief Financial Officer, will participate in one-on-one meetings with investors during the RBC Capital Markets Global Healthcare Conference in New York on Tuesday, February 25, 2014. No formal presentation is scheduled, and the one-on-one meetings will not be webcast.
Mr. Browne will participate in the neuromodulation panel discussion at the Citi 2014 Global Healthcare Conference in New York on Wednesday, February 26, 2014 at 9:40 AM Eastern Time. This panel discussion will not be webcast.
Dan Moore, Cyberonics' President & Chief Executive Officer, will present at the Barclays Global Healthcare Conference in Miami on Tuesday, March 11, 2014 at 2:30 PM Eastern Time. A live audio webcast of the presentation can be accessed by clicking on the Investor Relations link on the Cyberonics home page at http://www.cyberonics.com on March 11, 2014.
About Cyberonics, Inc. and the VNS Therapy® System
Cyberonics, Inc. is a medical technology company with core expertise in neuromodulation. The company developed and markets the VNS Therapy System, which is FDA-approved for the treatment of refractory epilepsy and treatment-resistant depression. The VNS Therapy System uses an implanted medical device that delivers pulsed electrical signals to the vagus nerve. Cyberonics markets the VNS Therapy System in selected markets worldwide.
Additional information on Cyberonics and the VNS Therapy System is available at www.cyberonics.com.
Greg Browne, CFO
100 Cyberonics Blvd., Houston, TX 77058
Main: (281) 228-7262 / Fax: (281) 218-9332
©2012 PR Newswire. All Rights Reserved.